Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

Basit Öğe Kaydı
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridKöstek, Osman/0000-0002-1901-5603
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridDemircan, Nazim/0000-0001-6630-5278
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidKöstek, Osman/AAA-3604-2019
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidDemircan, Nazim/HHY-8715-2022
dc.contributor.authorKostek, Osman
dc.contributor.authorYilmaz, Erdem
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorDemircan, Nazim Can
dc.contributor.authorGokyer, Ali
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorTuncbilek, Nermin
dc.date.accessioned2024-06-12T11:14:10Z
dc.date.available2024-06-12T11:14:10Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeTo evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).MethodsThirty-six patients treated with a tyrosine kinase inhibitor were included. Eighteen of them received sunitinib and the rest/remaining received pazopanib in the first line of mRCC treatment. Baseline and follow-up computed tomography studies of the patients were performed to measure cross-sectional areas (cm(2)) of muscle tissues.ResultsAbout 69% of patients were male and median age was 60 (49-68)years. Median time interval between two CT imagings was 6.1 (3.1-7.7)months and it was similar between the two groups (for sunitinib, 4.9 (2.5-6.9)months vs for pazopanib, 7.3 (3.2-9.5)months, p=0.16, respectively). Disease control rate was 77.7% in all patients. Of these, 66.6% in sunitinib group was consisted of four partial responses and eight stable diseases. In addition, 88.8% in pazopanib group was consisted of three partial responses and 13 stable diseases. A significant decrease in SMA and LBM was observed after sunitinib therapy, whereas SMA and LBM values of pazopanib group did not change significantly (p=0.02 and p=0.70, respectively). No significant differences were observed between patients with sunitinib, and pazopanib group median PFS [11.9 (95% CI 6.1-17.6) vs 8.1months (95% CI 7.2-9.1), respectively; p=0.28] and median OS [28.6 (95% CI 24.3-32.9) vs 25.5months (95% CI 18.9-52.7), respectively; p=0.42]. Dose-limiting toxicities were significantly more frequent in sunitinib group than in pazopanib group (66.7% vs 22.2%, p=0.02, respectively).ConclusionsLoss of SMA and LBM with sunitinib was more substantial than with pazopanib. Treatment efficacies of both drugs were similar, but dose-limiting toxicity was more frequent in sunitinib group. Loss of SMA had no significant association with prognosis. Further studies are needed to clarify the possible association between SMA and prognosis in mRCC patients who receive sunitinib or pazopanib.en_US
dc.identifier.doi10.1007/s00280-019-03779-5
dc.identifier.endpage742en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue4en_US
dc.identifier.pmid30680522en_US
dc.identifier.scopus2-s2.0-85060585749en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage735en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-019-03779-5
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23831
dc.identifier.volume83en_US
dc.identifier.wosWOS:000460805100013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSkeletal Muscle Areaen_US
dc.subjectLean Body Massen_US
dc.subjectSunitiniben_US
dc.subjectPazopaniben_US
dc.subjectRenal Cell Canceren_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectCell Carcinomaen_US
dc.subject1st-Line Treatmenten_US
dc.subjectInterferon-Alphaen_US
dc.subjectTyrosine Kinaseen_US
dc.subjectFactor Receptoren_US
dc.subjectSarcopeniaen_US
dc.subjectMetaanalysisen_US
dc.subjectInhibitoren_US
dc.subjectAssociationen_US
dc.titleChanges in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu